
Opinion|Videos|March 24, 2025
Rapid Efficacy and Safety Considerations With the Use of JAK Inhibitors in Atopic Dermatitis Care
Panelists discuss how Janus kinase (JAK) inhibitors such as upadacitinib, abrocitinib, and baricitinib offer rapid, oral treatment for moderate to severe atopic dermatitis, differing from injectable biologics in administration, broader immunosuppression, and risk of adverse events like thromboembolism. They provide effective symptom control but require safety monitoring.
Advertisement
Episodes in this series

Video content above in prompted by the following:
- How have JAK inhibitors (upadacitinib, abrocitinib, baricitinib) changed the treatment of moderate to severe atopic dermatitis, and in what ways to they differ from traditional biologics in terms of administration, safety, and efficacy?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Screening and Diagnosis of Hypercortisolism in Type 2 Diabetes
2
Prevalence and Recognition of Hypercortisolism
3
Distinguishing CSU From Chronic Inducible Urticaria Subtypes
4
Diagnosing the Hallmark Signs and Symptoms of CSU
5


























































































